-
The Synthetic Routes of Benzeneacetic acid, α-methylene-, 8-methyl-8-azabicyclo[3.2.1]oct-3-yl ester, hydrochloride, endo-
Time of Update: 2023-04-25
Here are some of the most commonly used synthetic routes: Knoevenagel Condensation: This is one of the most widely used methods for the synthesis of benzeneacetic acid, α-methylene-, 8-methyl-8-azabicyclo[3.
-
The Instruction of (5α,17β)-17-Methylspiro[androstane-3,3′-[3H]diazirin]-17-ol
Time of Update: 2023-04-25
It is used in pharmaceuticals to develop new drugs and treatments for various diseases, in the cosmetic industry to enhance the aroma and performance of various personal care products, in the food and beverage industry
-
New drugs The "first" new drugs approved by the FDA in 2022: involving TCR therapy, fecal bacterial therapy, bispecific antibodies, gene therapy, etc
Time of Update: 2023-02-03
Anti-CD20 monoclonal antibody for the treatment of RMSIn February 2022, the FDA approved the PK (pyruvate kinase) activator Pyrukynd (mitapivat) for the treatment of adult patients with PK deficiency and hemolytic anemia.
-
Express $130 million to help develop an innovative drug discovery platform for undruggable targets
Time of Update: 2023-02-03
com/companynews/belharra-therapeutics-debuts-with-130-million-in-funding/ Belharra's integrated chemical proteomics-based drug development engine overcomes the limitations of traditional high-throughput screening by exploring protein/ligand interactions in the cell's natural environment through a unique library of photoaffinity-based chemical probes.
-
The domestic IBD market is expected to exceed 10 billion next year, and drug research and development is still in the early stages
Time of Update: 2023-02-03
Inflammatory bowel disease (IBD) includes Crohn's disease (CD) and ulcerative colitis (UC) is a recurrent and inflammatory disease characterized by intestinal inflammation and epithelial injury that a
-
12 antibody drugs approved for the first time! 20% pipeline growth inventory of antibody drugs approved in 2022
Time of Update: 2023-02-03
Antibody drugs under FDA/EMA approval Source: ReferencesIn addition to new drugs already under approval, 17 antibody drugs in the field of oncology are expected to submit marketing applications to regulatory authorities by the end of this year or next year (Table 4), including 5 bispecific antibodies and 2 ADCs. Table 4.
-
Professor Yao Chen and Mr. Ge Yongbin had an in-depth conversation on "Compliance and Challenges of Real-World Data Research"!
Time of Update: 2023-02-03
As a medical research, the data is not only limited to the hospital, but also includes additional data collected according to the purpose of the study, especially follow-up data, when it is not enough to have universal informed consent, but also to explain it clearly to the data provider, because they have the individual right to know.
-
Inventory of the research progress of small molecule tumor immunotherapy drugs, what kind of research and development trends are revealed?
Time of Update: 2023-02-03
Originally developed by Aduro Biotechnology and later licensed to Novartis, ADU-S100 is a cyclic dinucleotide immunomodulator administered by direct intratumoral injection, either as a single agent or in combination with cytotoxic chemotherapy, targeted therapy, or checkpoint inhibitors, and is currently undergoing II clinical trials for metastatic head and neck cancer and squamous cell carcinoma (NCT03937141).
-
Long-acting HGH Imperative: Milestone! Longpei auxin "beats" the daily preparation head-to-head
Time of Update: 2023-02-03
Longpei auxin is superior to HGH daily formulation, Longpei auxin "beats" HGH daily preparations for the first time head-to-head, and is currently the only product that has demonstrated long-acting efficacy compared to HGH daily preparations through well-designed randomized controlled trialsProfessor Li Yanhong, as an important participant in the phase 3 key clinical trial in China, has a very intuitive feeling about Longpei auxin, she said: "The advent of polyethylene glycol (PEG)ated growth hormone can be said to be a milestone!
-
Hit the national health insurance negotiation! Blockbuster products such as new crown oral drugs participated in "soul bargaining", and some companies left in silence
Time of Update: 2023-02-03
The 2022 national medical insurance on-site negotiations, which have been postponed for more than a month, officially kicked off today (5th). According to the "List of Declared Drugs Approved by the A
-
Remote decentralized clinical trials on the rise of the EU and UK
Time of Update: 2023-02-03
Decentralized clinical trials (DCTs) differ from traditional clinical trials in that they contain a "remote" element that enables activities such as consent, treatment management, data collection, and monitoring to be conducted remotely, for example, at a patient's home.
-
Popular track: NASH research conditions and treatment strategies
Time of Update: 2023-02-03
Peptide Research Society In recent years, the prevalence of nonalcoholic fatty liver disease (NAFLD) has increased due to improved living standards and changes in lifestyle and diet.
-
Top 10 M&A events in the global health sector in 2022
Time of Update: 2023-02-03
In the near future, Medical Geography will continue to publish annual inventory articles, so that we can witness the history and explore the future On August 8, Pfizer announced that it had reached an agreement with Global Blood Therapeutics (GBT) to acquire all outstanding shares of GBT under the terms of the transaction, including debt and net cash from the acquisition, for a total value of approximately $5.
-
Biotech industry 2023, the darkest and the new rotation
Time of Update: 2023-02-03
The biotechnology industry has turned from bull to bear, and the core inducing factor is the continuous "high-pressure" policy:Centralized procurement + medical insurance negotiation is the "sword of Damocles" hanging over the heads of pharmaceutical companies; The release of the "Guidelines for Clinical R&D of Antitumor Drugs Oriented by Clinical Value" is the beginning of the supply-side reform of innovative drugs.
-
32 clinical trials worth watching in 2023
Time of Update: 2023-02-03
Yesterday, we reviewed the top 10 potential blockbuster therapies that could be approved this year. Today, let's look ahead to the clinical trials worth watching in 2023. Recently, Evaluate released a
-
Gilead acquires CCR8 antibodies for $67 million
Time of Update: 2023-02-03
Original English: _mstmutation="1" _msthash="220728" _msttexthash="22719762"> On December 27, 2022, Gilead announced a partnership with Jounce Therapeutics amended its license agreement for GS-1811 (formerly known as JTX-1811) to buy out GS-1811 for $67 million, and Gilead will be solely responsible for all research, development and commercialization of GS-1811 worldwide, with full R&D and commercial rights.
-
List of new drugs recommended for marketing by the EU CHMP in 2022
Time of Update: 2023-02-03
On December 16, the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) concluded its last working meeting of the year, which issued review opinions on the EU marketing applications of six new drugs.
-
Annual inventory: analysis of financing events in the field of artificial intelligence pharmaceutical R&D platform in 2022
Time of Update: 2023-02-03
On April 12, 2021, StoneWise, a platform technology company driven by artificial intelligence technology for the research and development of innovative drugs, announced the completion of Series B+ and Series B financing, with a total financing of US$100 million.
-
2023 Pharmaceutical Annual View: Finding the Next Increment
Time of Update: 2023-02-03
The long road is dangerous, and the medicine melts the circleIn addition to using new technologies such as continuous flow and synthetic biology to reduce costs, APIs/intermediates should be more open and diversified, and the MAH policy and the upstream and downstream of the industrial chain can be used to form a bundled relationship of equity and sharing to develop incremental business.
-
Cytomx shares jumped 60 percent with a $1.2 billion partnership with Moderna
Time of Update: 2023-02-03
summarysummaryCytomx's proantibodies have reached cooperation with many large companies, including BMS, Astellas, Moderna, etc.
summarysummaryCytomx's proantibodies have reached cooperation with many large companies, including BMS, Astellas, Moderna, etc.
Cytomx's proantibodies have reached cooperation with many large companies, including BMS, Astellas, Moderna, etc.
